Method of treating estrogen receptor positive carcinoma with 17 α-dihydroequilin
US7005429B2 · kind B2 · utility
57Cited by
0References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 26, 2001 |
| Grant date | Feb 28, 2006 |
| Priority date | — |
| Expiry date | Oct 10, 2023 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/567
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention provides a method of treating estrogen receptor positive carcinoma in a mammal in need thereof which comprises administering an antineoplastic amount of 17(α-dihydroequilin or a mammalian metabolic conjugate thereof orally, parenterally, transdermally, topically, rectally, intravaginally, intranasally, or intrabronchially. As such, the compounds of this invention are useful in treating estrogen receptor positive carcinomas such as carcinomas of the breast, uterus, ovary, fallopian tube, cervix, vagina, liver, pituitary, central nervous system, hypothalamus, bone, skin, kidney, urethra, prostate, and the like.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.